Современное состояние проблемы комбинированного лечения местно-распрастраненного плоскоклеточного рака полового члена

  • А. А. Анищенко ГОО ВПО «Донецкий национальный медицинский университет им. М Горького
  • А. В. Башеев ГОО ВПО «Донецкий национальный медицинский университет им М. Горького»
  • А. А. Рязанцев Республиканский онкологический центр имени профессора Г.В. Бондаря
  • А. Н. Крюков Республиканский онкологический центр имени профессора Г.В. Бондаря
  • А. А. Хачатрян Республиканский онкологический центр имени профессора Г.В. Бондаря

Аннотация

Рак полового члена (РПЧ) – злокачественная опухоль полового члена, которая встречается довольно редко,  заболеваемость данной патологией составляет менее 1,0 на 100 000 мужчин. Статья содержит основную информацию об эпидемиологии, патоморфологии, классификации рака полового члена. В данном исследовании представлен обзор литературы о современных принципах, подходах и возможностях комбинированного лечения местно-распространённого плоскоклеточного рака полового члена.

Литература

1. Белова Е.А. Обоснование применения органосберегающих операций в комбинированном лечении больных инвазивным плоскоклеточным раком полового члена.//Автореферат. дисс. канд.мед.наук. С-П., 2010. с. 2-21.
2. Волкова М.И. Выбор тактики лечения рака полового члена в зависимости от клинико- морфологических факторов прогноза// Матер.конф. «Опухоли половых органов у мужчин» ч. III, Н.Новгород, 2007.
3. Давыдов М.И., Ганцев Ш. Х., Вельшер Л.З. и др. Онкология : учебник. - Москва : ГЭОТАР-Медиа, 2020. - 920 с.
4. Каприн А.Д., Замятин О.А., Подшивалов А.В. Рак полового члена. Методы лечения и перспективы// Андрология и генитальная хирургия, 2001,№1, с.88-94.
5. Каприн А.Д., Миленин К.Н. Комбинированное и комплексное лечение рака полового члена // Андрология и генитальная хирургия, 2005,№3, с.21-25.
6. Каприн А.Д., Старинский В.В., Шахзадова А.О. и др. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность) – М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, − 2021. − илл. − 252 с
7. Каприн А.Д.,Матвеев В.Б.,Алексеев Б.Я. и др. Клинические рекомендации. Рак полового члена. - Москва: 2020. - 56 с.
8. Карлов П.А, Карлов А.П., Дубинский В.Я., Пешехонов К.С. Урологические ведомости. – 2017. – Т. 7. – № 1. – С. 30–32. doi: 10.17816/uroved7130-32
9. Миленин К.Н. Сочетанная лучевая терапия при органосохраняющем лечении рака полового члена.//Автореферат. дисс. . канд.мед.наук. М., 2006. с. 2-20.
10. Правосудова Н. А. и др. Особенности послеоперационных осложнений в отделении онкоурологии и онкогинекологии //Медицинский альманах. – 2016. – №. 3 (43).
11. Хачатурян А.В., Булычкин П.В. Комбинированное органосохранное лечение рака полового члена (случай из практики). Онкоурология. 2015;11(2). doi.org/10.17650/1726-9776-2015-11-2
12. Чиссов В.И., Давыдов М.И. Онкология: национальное руководство. Краткое издание. - М.: ГЭОТАР-Медиа, 2017. - 576 с.
13. Ajani J.A., Winter K.A., Gunderson L.L. et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914-21.
14. Alnajjar, H.M., et al. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol, 2012. 62: 923.
15. Azrif, M., et al. External-beam radiotherapy in T1-2 N0 penile carcinoma. Clin Oncol (R Coll Radiol), 2006. 18: 320.
16. Backes, D.M., et al. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control, 2009. 20: 449.
17. Bandieramonte, G., et al. Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. Eur Urol, 2008. 54: 875.
18. Baumgarten A., Chipollini J., Yan S. et al. Penile Sparing Surgery for Penile Cancer: A Multicenter International Retrospective Cohort. Journal Urology. 2018;199(5):1233-1237.
19. Bermejo, C., et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol, 2007. 177: 1335.
20. Brierley J.D., Gospodorawicz M.K., Wittekind C. TNM Classification of Malignant Tumours, 8 еd. International Union Against Cancer, Wiley-Blackwell, 2016:188-9.
21. Brierley, J., et al., TNM Classifi cation of Malignant Tumours, 8th Edn. 2016.
22. Burt, L.M., et al. Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys, 2014. 88: 94.
23. Cancer Incidence in Five Continents Vol. VIII. IARC Scientifi c Publication No. 155. Vol. Vol III. 2002, Th e International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.
24. Carthon B. C. et al. Epidermal growth factor receptor‐targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis //BJU international. – 2014. – Т. 113. – № . 6. – С. 871-877.
25. Chaux, A., et al. Epidemiologic profi le, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World J Urol, 2013. 31: 861.
26. Chhabra A., Schwartz D., Leaf A., et al. Neoadjuvant concurrent chemoradiation for curative treatment of penile squamous cell carcinoma. Case Rep Oncol Med. 2014;2014:479376.
27. Chung T. S. et al. Synchronous penile metastasis from a rectal carcinoma //International journal of colorectal disease. – 2008. – Т. 23. – №. 3. – С. 333-334.
28. Colecchia, M., et al. pT1 penile squamous cell carcinoma: a clinicopathologic study of 56 cases treated by CO2 laser therapy. Anal Quant Cytol Histol, 2009. 31: 153.
29. Comparison with Historical Data of Low Dose Rate Brachytherapy. Clin Oncol (R Coll Radiol), 2015. 27: 387.
30. Cordoba, A., et al. Low-dose brachytherapy for early stage penile cancer: a 20-year singleinstitution study (73 patients). Radiat Oncol, 2016. 11: 96.
31. Crook J., Ma C., Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World Journal of Urology. 2009;27(2):189-96.
32. Crook, J., et al. MP-21.03: Penile brachytherapy: results for 60 patients. Urology, 2007. 70: 161.
33. Crook, J., et al. Penile brachytherapy: technical aspects and postimplant issues. Brachytherapy, 2010. 9: 151.
34. Crook, J., et al. Radiation therapy in the management of the primary penile tumor: an update. World J Urol, 2009. 27: 189.
35. Crook, J.M., et al. American Brachytherapy Society-Groupe Europeen de Curietherapie-European Society of Th erapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy. Brachytherapy, 2013. 12: 191.
36. Cubilla A.L., Reuter V., Velazquez E. et al. Histologic classification of penile carcinoma and its relation to outcome in 61 patients with primary resection. International Journal of Surgical Pathology. 2001;9(2):111-120.
37. Cui, Y., et al. Saphenous vein sparing during laparoscopic bilateral inguinal lymphadenectomy for penile carcinoma patients. Int Urol Nephrol, 2016. 48: 363.
38. de Crevoisier, R., et al. Long-term results of brachytherapy for carcinoma of the penis confi ned to the glans (N- or NX). Int J Radiat Oncol Biol Phys, 2009. 74: 1150.
39. Delaunay, B., et al. Brachytherapy for penile cancer: effi cacy and impact on sexual function. Brachytherapy, 2014. 13: 380.
40. Di Lorenzo G., Buonerba C., Federico P. et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU International. 2012;110(11 Pt B):E661-6.
41. Di Lorenzo G., Federico P., Buonerba C. et al. Paclitaxel in pretreated metastatic penile cancer. final results of a phase 2 study. European Urology. 2011;60:1280- 1284.
42. Di Lorenzo, G., et al. Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study. J Transl Med, 2013. 11: 161.
43. Di Lorenzo, G., et al. Paclitaxel in pretreated metastatic penile cancer: fi nal results of a phase 2 study. Eur Urol, 2011. 60: 1280.
44. Dickstein, R.J., et al. Prognostic factors infl uencing survival from regionally advanced squamous cell carcinoma of the penis aft er preoperative chemotherapy. BJU Int, 2016. 117: 118.
45. Djajadiningrat, R.S., et al. Penile sparing surgery for penile cancer-does it aff ect survival? J Urol, 2014. 192: 120.
46. Eliason M., Bowen G., Bowen A. et al. Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy. Arch Dermatol. 2009;145(8):950-2.
47. Frimberger, D., et al. Penile carcinoma. Is Nd:YAG laser therapy radical enough? J Urol, 2002. 168: 2418.
48. Gonzaga-Silva L.F., Lima G.R.M., Tavares J.M. et al. Locally advanced penile carcinoma: classic emasculation or testis-sparing surgery? International Brazilian Journal of Urology. 2012;38(6):750-759.
49. Gotsadze, D., et al. Is conservative organ-sparing treatment of penile carcinoma justifi ed? Eur Urol, 2000. 38: 306.
50. Gou, H.F., et al. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS One, 2013. 8: e62175. .
51. Graafl and, N.M., et al. Prognostic signifi cance of extranodal extension in patients with pathological node positive penile carcinoma. J Urol, 2010. 184: 1347.
52. Haas G.P., Blumenstein B.A., Gagliano R.G. et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. Journal of Urology. 1999;161(6):1823-5.
53. Hakenberg O.W., Compérat E., Minhas S. et al. Guidelines on Penile Cancer. EAU 2017:20-21.
54. Hasan, S., et al. Th e role of brachytherapy in organ preservation for penile cancer: A meta-analysis and review of the literature. Brachytherapy, 2015. 14: 517.
55. Hegarty, P.K., et al. Controversies in ilioinguinal lymphadenectomy. Urol Clin North Am, 2010. 37: 421.
56. Iorga L, et al. Penile carcinoma and HPV infection (Review).Exp Ther Med. 2020 Jul;20(1):91-96.
57. Joerger M., Warzinek T., Klaeser B. et al. Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology. 2004;63(4):778-80.
58. Kamel M.H., Bissada N., Warford R. et al. Organ Sparing Surgery for Penile Cancer: A Systematic Review. Journal Urology. 2017;198(4):770-779.
59. Kamsu-Kom, L., et al. Clinical Experience with Pulse Dose Rate Brachytherapy for Conservative Treatment of Penile Carcinoma and
60. Comparison with Historical Data of Low Dose Rate Brachytherapy. Clin Oncol (R Coll Radiol), 2015. 27: 387.
61. Koifman, L., et al. Radical open inguinal lymphadenectomy for penile carcinoma: surgical technique, early complications and late outcomes. J Urol, 2013. 190: 2086.
62. Koifman, L., et al. Epidemiological aspects of penile cancer in Rio de Janeiro: evaluation of 230 cases. Int Braz J Urol, 2011. 37: 231.
63. Kumar, V., et al. Prospective study comparing video-endoscopic radical inguinal lymph node dissection (VEILND) with open radical ILND (OILND) for penile cancer over an 8-year period. BJU Int, 2017. 119: 530.
64. Lebelo, R.L., et al. Diversity of HPV types in cancerous and pre-cancerous penile lesions of South African men: implications for future HPV vaccination strategies. J Med Virol, 2014. 86: 257.
65. Leijte, J.A., et al. Evaluation of current TNM classifi cation of penile carcinoma. J Urol, 2008. 180: 933.
66. Leijte, J.A., et al. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol, 2007. 52: 488.
67. Leijte, J.A., et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol, 2008. 54: 161.
68. Lestrade L. et al. Radiochemotherapy and brachytherapy could be the standard treatment for anal canal cancer in elderly patients? A retrospective single-centre analysis //Medical Oncology. – 2013. – Т. 30. – № . 1. – С. 402.
69. Lont, A.P., et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer, 2006. 119: 1078.
70. Lucky, M.A., et al. Referrals into a dedicated British penile cancer centre and sources of possible delay. Sex Transm Infect, 2009. 85: 527.
71. Lughezzani, G., et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile 107 squamous cell carcinoma: a single institution experience. J Urol, 2014. 191: 977.
72. Lukowiak TM, Perz AM, Aizman L, et al.. Mohs micrographic surgery for male genital tumors: Local recurrence rates and patient-reported outcomes. J Am Acad Dermatol. 2021 Apr;84(4):1030-1036. doi: 10.1016/j.jaad.2020.11.060.
73. Luo W.X., He J.P., Li X., Liu J.Y. Neoadjuvant chemotherapy with cetuximab for locally advanced penile cancer. J Cancer Res Ther. 2015;11(4):1041.
74. Machan, M., et al. Penile Squamous Cell Carcinoma: Penis-Preserving Treatment With Mohs Micrographic Surgery. Dermatol Surg, 2016. 42: 936.
75. Manjunath, A., et al. Topical Therapy for non-invasive penile cancer (Tis)-updated results and toxicity. Transl Androl Urol. 2017 Oct;6(5):803-808. doi: 10.21037/tau.2017.06.24.
76. Meijer, R.P., et al. Long-term follow-up aft er laser therapy for penile carcinoma. Urology, 2007. 69: 759.
77. Mobilio G, Ficarra V. Genital treatment of penile carcinoma. CurrOpinUrol 2001;11(3):299-304.
78. Modig, H., et al. Carcinoma of the penis. Treatment by surgery or combined bleomycin and radiation therapy. Acta Oncol, 1993. 32: 653.
79. Mohs, F.E., et al. Mohs micrographic surgery for penile tumors. Urol Clin North Am, 1992. 19: 291.
80. Montana G.S., Thomas G.M., Moore D.H. et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. International Journal of Radiation Oncology, Biology, Physics. 2000;48(4):1007-13.
81. Munoz, N., et al. Chapter 1: HPV in the etiology of human cancer. Vaccine, 2006. 24 Suppl 3: S3/1.
82. NCCN guidelines version 2.2019 Penile Cancer
83. Necchi, A., et al. Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. Clin Genitourin Cancer, 2016. 14: 231.
84. Necchi, A., et al. Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma Aft er Regional Lymphadenectomy. Clin Genitourin Cancer, 2016. 14: 518.
85. Necchi, A., et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol, 2011. 29: e650.
86. Nicolai, N., et al. A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. Clin Genitourin Cancer, 2016. 14: 323.
87. Nordenvall, C., et al. Cancer risk among patients with condylomata acuminata. Int J Cancer, 2006. 119: 888.
88. Ornellas, A.A., et al. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-termexperience. J Surg Oncol, 2008. 97: 487.
89. Ozsahin, M., et al. Treatment of penile carcinoma: to cut or not to cut? Int J Radiat Oncol Biol Phys, 2006. 66: 674.
90. Pagliaro, L.C., et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol, 2010. 28: 3851.
91. Paoli, J., et al. Penile intraepithelial neoplasia: results of photodynamic therapy. Acta Derm Venereol, 2006. 86: 418.
92. Parkin, D.M., et al. Chapter 2: Th e burden of HPV-related cancers. Vaccine, 2006. 24 Suppl 3: S3/11.
93. Pedrick T.J., Wheeler W., Riemenschneider H. Combined modality therapy for locally advanced penile squamous cell carcinoma. American Journal of Clinical Oncology. 1993;16(6):501-5.
94. Philippou, P., et al. Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control. J Urol, 2012. 188: 803.
95. Piva, L., et al. [Th erapeutic alternatives in the treatment of class T1N0 squamous cell carcinoma of the penis: indications and limitations]. Arch Ital Urol Androl, 1996. 68: 157.
96. Pizzocaro, G., et al. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol, 1988. 27: 823.
97. Pizzocaro, G., et al. Taxanes in combination with cisplatin and fl uorouracil for advanced penile cancer: preliminary results. Eur Urol, 2009.55: 546.
98. Rees, R.W., et al. pT2 penile squamous cell carcinomas: cavernosus vs. spongiosus invasion. Eur Urol Suppl, 2008. 7: 111.
99. Robinson R., Marconi L., MacPepple E. et al. Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. European Urology. 2018;74(1):76-83.
100. Rosevear, H.M., et al. Utility of (1)(8)F-FDG PET/CT in identifying penile squamous cell carcinoma metastatic lymph nodes. Urol Oncol, 2012. 30: 723.
101. Rothenberger, K.H., et al. [Laser therapy of penile carcinoma]. Urologe A, 1994. 33: 291.
102. Saisorn, I., et al. Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int, 2006. 97: 1225.
103. Schlenker, B., et al. Organ-preserving neodymium-yttrium-aluminium-garnet laser therapy for penile carcinoma: a long-term follow-up. BJU Int, 2010. 106: 786.
104. Shabbir, M., et al. Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes. Eur Urol, 2011.59: 142.
105. Sharma, P., et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer aft er lymph node dissection: a multi-institutional study. Urol Oncol, 2015. 33: 496 e17.
106. Shindel, A.W., et al. Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol, 2007. 178: 1980.
107. Stankiewicz, E., et al. HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Mod Pathol, 2009. 22: 1160
108. Stern, R.S. Th e risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol, 2012. 66: 553.
109. Stuiver, M.M., et al. Early wound complications aft er inguinal lymphadenectomy in penile cancer: a historical cohort study and risk-factor analysis. Eur Urol, 2013. 64: 486.
110. Tauber, R., et al. Inguinal lymph node dissection: epidermal vacuum therapy for prevention of wound complications. J Plast Reconstr Aesthet Surg, 2013. 66: 390.
111. Tietjen, D.N., et al. Laser therapy of squamous cell dysplasia and carcinoma of the penis. Urology, 1998. 52: 559.
112. Tobias-Machado, M., et al. Video endoscopic inguinal lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma. J Urol, 2007. 177: 953.
113. Van Bezooijen, B.P., et al. Laser therapy for carcinoma in situ of the penis. J Urol, 2001. 166: 1670.
114. Van Howe, R.S., et al. Th e carcinogenicity of smegma: debunking a myth. J Eur Acad Dermatol Venereol, 2006. 20: 1046.
115. Veeratterapillay, R., et al. Oncologic Outcomes of Penile Cancer Treatment at a UK Supraregional Center. Urology, 2015. 85: 1097.
116. Weldrick, C., et al. A comparison of fi brin sealant versus standard closure in the reduction of postoperative morbidity aft er groin dissection: A systematic review and meta-analysis. Eur J Surg Oncol, 2014. 40: 1391.
117. Windahl, T., et al. Combined laser treatment for penile carcinoma: results aft er long-term followup. J Urol, 2003. 169: 2118.
118. Winters B.R., Kearns J.T., Holt S.K. et al. Is there a benefit to adjuvant radiation in stage III penile cancer after lymph node dissection? Findings from the National Cancer Database. Urology Oncology. 2018;36(3):92.e11-92.e16.
119. Winters, B.R., et al. Predictors of Nodal Upstaging in Clinical Node Negative Patients With Penile Carcinoma: A National Cancer Database Analysis. Urology, 2016. 96: 29.
120. Wu J., Cheng K., Yuan L. et al. Recurrent Penile Squamous Cell Carcinoma Successfully Treated With Cetuximab, Chemotherapy, and Radiotherapy. Clinical Genitourinary Cancer. 2016 Feb;14(1):e135-7.
121. Yao, K., et al. Modifi ed technique of radical inguinal lymphadenectomy for penile carcinoma: morbidity and outcome. J Urol, 2010. 184: 546.
122. Zargar-Shoshtari K., Djajadiningrat R., Sharma P. et al. Establishing Criteria for Bilateral Pelvic Lymph Node Dissection in the Management of Penile Cancer: Lessons Learned from an International Multicenter Collaboration. Journal of Urology. 2015;194(3):696-701.
123. Zhu, Y., et al. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urol Int, 2010. 85: 334.
124. Zou, Z.J., et al. Radiocolloid-based dynamic sentinel lymph node biopsy in penile cancer with clinically negative inguinal lymph node: an updated systematic review and meta-analysis. Int Urol Nephrol, 2016. 48: 2001.
125. Zreik A, Rewhorn M, Vint R, Khan R, Hendry D. Carbon dioxide laser treatment of penile intraepithelial neoplasia. Surgeon. 2017 Dec;15(6):321-324. doi: 10.1016/j.surge.2016.11.001.


1. Belova E.A. Rationale for the use of organ-sparing operations in the combined treatment of patients with invasive squamous cell carcinoma of the penis.//Abstract. diss. Candidate of Medical Sciences S-P., 2010. p. 2-21.

2. Volkova M.I. The choice of tactics for the treatment of penile cancer, depending on the clinical and morphological prognostic factors / / Mater.konf. "Tumors of the genital organs in men" part III, N. Novgorod, 2007.
3. Davydov M.I., Gantsev Sh.Kh., Velsher L.Z. etc. Oncology: textbook. - Moscow: GEOTAR-Media, 2020. - 920 p.
4. Kaprin A.D., Zamyatin O.A., Podshivalov A.V. Cancer of the penis. Methods of treatment and prospects / / Andrology and genital surgery, 2001, No. 1, pp. 88-94.
5. Kaprin A.D., Milenin K.N. Combined and complex treatment of penile cancer // Andrology and Genital Surgery, 2005, No. 3, pp. 21-25.

6. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2020 (morbidity and mortality) - M.: MNIOI im. P.A. Herzen - branch of the Federal State Budgetary Institution "NMITs Radiology" of the Ministry of Health of Russia, - 2021. - ill. – 252.
7. Kaprin A.D., Matveev V.B., Alekseev B.Ya. etc. Clinical recommendations. Cancer of the penis. - Moscow: 2020. - 56 p.
8. Karlov P.A., Karlov A.P., Dubinsky V.Ya., Peshekhonov K.S. Urological statements. – 2017. – V. 7. – No. 1. – P. 30–32. doi:10.17816/uroved7130-32
9. Milenin K.N. Combined radiation therapy in organ-preserving treatment of penile cancer.//Abstract. diss. . Candidate of Medical Sciences M., 2006. p. 2-20.
10. Pravosudova N. A. et al. Features of postoperative complications in the department of oncourology and oncogynecology //Medical almanac. – 2016. – no. 3 (43).
11. Khachaturyan A.V., Bulychkin P.V. Combined organ-preserving treatment for penile cancer (case report). Oncourology. 2015;11(2). doi.org/10.17650/1726-9776-2015-11-2

12. Chissov V.I., Davydov M.I. Oncology: a national guide. Short edition. - M.: GEOTAR-Media, 2017. - 576 p.
13. Ajani J.A., Winter K.A., Gunderson L.L. et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914-21.
14. Alnajjar, H.M., et al. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol, 2012. 62: 923.
15. Azrif, M., et al. External-beam radiotherapy in T1-2 N0 penile carcinoma. Clin Oncol (R Coll Radiol), 2006. 18: 320.
16. Backes, D.M., et al. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control, 2009. 20: 449.
17. Bandieramonte, G., et al. Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. Eur Urol, 2008. 54: 875.
18. Baumgarten A., Chipollini J., Yan S. et al. Penile Sparing Surgery for Penile Cancer: A Multicenter International Retrospective Cohort. Journal Urology. 2018;199(5):1233-1237.
19. Bermejo, C., et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol, 2007. 177: 1335.
20. Brierley J.D., Gospodorawicz M.K., Wittekind C. TNM Classification of Malignant Tumours, 8 еd. International Union Against Cancer, Wiley-Blackwell, 2016:188-9.
21. Brierley, J., et al., TNM Classifi cation of Malignant Tumours, 8th Edn. 2016.
22. Burt, L.M., et al. Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys, 2014. 88: 94.
23. Cancer Incidence in Five Continents Vol. VIII. IARC Scientifi c Publication No. 155. Vol. Vol III. 2002, Th e International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France.
24. Carthon B. C. et al. Epidermal growth factor receptor‐targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis //BJU international. – 2014. – Т. 113. – № . 6. – С. 871-877.
25. Chaux, A., et al. Epidemiologic profi le, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World J Urol, 2013. 31: 861.
26. Chhabra A., Schwartz D., Leaf A., et al. Neoadjuvant concurrent chemoradiation for curative treatment of penile squamous cell carcinoma. Case Rep Oncol Med. 2014;2014:479376.
27. Chung T. S. et al. Synchronous penile metastasis from a rectal carcinoma //International journal of colorectal disease. – 2008. – Т. 23. – №. 3. – С. 333-334.
28. Colecchia, M., et al. pT1 penile squamous cell carcinoma: a clinicopathologic study of 56 cases treated by CO2 laser therapy. Anal Quant Cytol Histol, 2009. 31: 153.
29. Comparison with Historical Data of Low Dose Rate Brachytherapy. Clin Oncol (R Coll Radiol), 2015. 27: 387.
30. Cordoba, A., et al. Low-dose brachytherapy for early stage penile cancer: a 20-year singleinstitution study (73 patients). Radiat Oncol, 2016. 11: 96.
31. Crook J., Ma C., Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World Journal of Urology. 2009;27(2):189-96.
32. Crook, J., et al. MP-21.03: Penile brachytherapy: results for 60 patients. Urology, 2007. 70: 161.
33. Crook, J., et al. Penile brachytherapy: technical aspects and postimplant issues. Brachytherapy, 2010. 9: 151.
34. Crook, J., et al. Radiation therapy in the management of the primary penile tumor: an update. World J Urol, 2009. 27: 189.
35. Crook, J.M., et al. American Brachytherapy Society-Groupe Europeen de Curietherapie-European Society of Th erapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy. Brachytherapy, 2013. 12: 191.
36. Cubilla A.L., Reuter V., Velazquez E. et al. Histologic classification of penile carcinoma and its relation to outcome in 61 patients with primary resection. International Journal of Surgical Pathology. 2001;9(2):111-120.
37. Cui, Y., et al. Saphenous vein sparing during laparoscopic bilateral inguinal lymphadenectomy for penile carcinoma patients. Int Urol Nephrol, 2016. 48: 363.
38. de Crevoisier, R., et al. Long-term results of brachytherapy for carcinoma of the penis confi ned to the glans (N- or NX). Int J Radiat Oncol Biol Phys, 2009. 74: 1150.
39. Delaunay, B., et al. Brachytherapy for penile cancer: effi cacy and impact on sexual function. Brachytherapy, 2014. 13: 380.
40. Di Lorenzo G., Buonerba C., Federico P. et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU International. 2012;110(11 Pt B):E661-6.
41. Di Lorenzo G., Federico P., Buonerba C. et al. Paclitaxel in pretreated metastatic penile cancer. final results of a phase 2 study. European Urology. 2011;60:1280- 1284.
42. Di Lorenzo, G., et al. Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study. J Transl Med, 2013. 11: 161.
43. Di Lorenzo, G., et al. Paclitaxel in pretreated metastatic penile cancer: fi nal results of a phase 2 study. Eur Urol, 2011. 60: 1280.
44. Dickstein, R.J., et al. Prognostic factors infl uencing survival from regionally advanced squamous cell carcinoma of the penis aft er preoperative chemotherapy. BJU Int, 2016. 117: 118.
45. Djajadiningrat, R.S., et al. Penile sparing surgery for penile cancer-does it aff ect survival? J Urol, 2014. 192: 120.
46. Eliason M., Bowen G., Bowen A. et al. Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy. Arch Dermatol. 2009;145(8):950-2.
47. Frimberger, D., et al. Penile carcinoma. Is Nd:YAG laser therapy radical enough? J Urol, 2002. 168: 2418.
48. Gonzaga-Silva L.F., Lima G.R.M., Tavares J.M. et al. Locally advanced penile carcinoma: classic emasculation or testis-sparing surgery? International Brazilian Journal of Urology. 2012;38(6):750-759.
49. Gotsadze, D., et al. Is conservative organ-sparing treatment of penile carcinoma justifi ed? Eur Urol, 2000. 38: 306.
50. Gou, H.F., et al. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS One, 2013. 8: e62175. .
51. Graafl and, N.M., et al. Prognostic signifi cance of extranodal extension in patients with pathological node positive penile carcinoma. J Urol, 2010. 184: 1347.
52. Haas G.P., Blumenstein B.A., Gagliano R.G. et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. Journal of Urology. 1999;161(6):1823-5.
53. Hakenberg O.W., Compérat E., Minhas S. et al. Guidelines on Penile Cancer. EAU 2017:20-21.
54. Hasan, S., et al. Th e role of brachytherapy in organ preservation for penile cancer: A meta-analysis and review of the literature. Brachytherapy, 2015. 14: 517.
55. Hegarty, P.K., et al. Controversies in ilioinguinal lymphadenectomy. Urol Clin North Am, 2010. 37: 421.
56. Iorga L, et al. Penile carcinoma and HPV infection (Review).Exp Ther Med. 2020 Jul;20(1):91-96.
57. Joerger M., Warzinek T., Klaeser B. et al. Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology. 2004;63(4):778-80.
58. Kamel M.H., Bissada N., Warford R. et al. Organ Sparing Surgery for Penile Cancer: A Systematic Review. Journal Urology. 2017;198(4):770-779.
59. Kamsu-Kom, L., et al. Clinical Experience with Pulse Dose Rate Brachytherapy for Conservative Treatment of Penile Carcinoma and
60. Comparison with Historical Data of Low Dose Rate Brachytherapy. Clin Oncol (R Coll Radiol), 2015. 27: 387.
61. Koifman, L., et al. Radical open inguinal lymphadenectomy for penile carcinoma: surgical technique, early complications and late outcomes. J Urol, 2013. 190: 2086.
62. Koifman, L., et al. Epidemiological aspects of penile cancer in Rio de Janeiro: evaluation of 230 cases. Int Braz J Urol, 2011. 37: 231.
63. Kumar, V., et al. Prospective study comparing video-endoscopic radical inguinal lymph node dissection (VEILND) with open radical ILND (OILND) for penile cancer over an 8-year period. BJU Int, 2017. 119: 530.
64. Lebelo, R.L., et al. Diversity of HPV types in cancerous and pre-cancerous penile lesions of South African men: implications for future HPV vaccination strategies. J Med Virol, 2014. 86: 257.
65. Leijte, J.A., et al. Evaluation of current TNM classifi cation of penile carcinoma. J Urol, 2008. 180: 933.
66. Leijte, J.A., et al. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol, 2007. 52: 488.
67. Leijte, J.A., et al. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol, 2008. 54: 161.
68. Lestrade L. et al. Radiochemotherapy and brachytherapy could be the standard treatment for anal canal cancer in elderly patients? A retrospective single-centre analysis //Medical Oncology. – 2013. – Т. 30. – № . 1. – С. 402.
69. Lont, A.P., et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer, 2006. 119: 1078.
70. Lucky, M.A., et al. Referrals into a dedicated British penile cancer centre and sources of possible delay. Sex Transm Infect, 2009. 85: 527.
71. Lughezzani, G., et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile 107 squamous cell carcinoma: a single institution experience. J Urol, 2014. 191: 977.
72. Lukowiak TM, Perz AM, Aizman L, et al.. Mohs micrographic surgery for male genital tumors: Local recurrence rates and patient-reported outcomes. J Am Acad Dermatol. 2021 Apr;84(4):1030-1036. doi: 10.1016/j.jaad.2020.11.060.
73. Luo W.X., He J.P., Li X., Liu J.Y. Neoadjuvant chemotherapy with cetuximab for locally advanced penile cancer. J Cancer Res Ther. 2015;11(4):1041.
74. Machan, M., et al. Penile Squamous Cell Carcinoma: Penis-Preserving Treatment With Mohs Micrographic Surgery. Dermatol Surg, 2016. 42: 936.
75. Manjunath, A., et al. Topical Therapy for non-invasive penile cancer (Tis)-updated results and toxicity. Transl Androl Urol. 2017 Oct;6(5):803-808. doi: 10.21037/tau.2017.06.24.
76. Meijer, R.P., et al. Long-term follow-up aft er laser therapy for penile carcinoma. Urology, 2007. 69: 759.
77. Mobilio G, Ficarra V. Genital treatment of penile carcinoma. CurrOpinUrol 2001;11(3):299-304.
78. Modig, H., et al. Carcinoma of the penis. Treatment by surgery or combined bleomycin and radiation therapy. Acta Oncol, 1993. 32: 653.
79. Mohs, F.E., et al. Mohs micrographic surgery for penile tumors. Urol Clin North Am, 1992. 19: 291.
80. Montana G.S., Thomas G.M., Moore D.H. et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. International Journal of Radiation Oncology, Biology, Physics. 2000;48(4):1007-13.
81. Munoz, N., et al. Chapter 1: HPV in the etiology of human cancer. Vaccine, 2006. 24 Suppl 3: S3/1.
82. NCCN guidelines version 2.2019 Penile Cancer
83. Necchi, A., et al. Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. Clin Genitourin Cancer, 2016. 14: 231.
84. Necchi, A., et al. Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma Aft er Regional Lymphadenectomy. Clin Genitourin Cancer, 2016. 14: 518.
85. Necchi, A., et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol, 2011. 29: e650.
86. Nicolai, N., et al. A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. Clin Genitourin Cancer, 2016. 14: 323.
87. Nordenvall, C., et al. Cancer risk among patients with condylomata acuminata. Int J Cancer, 2006. 119: 888.
88. Ornellas, A.A., et al. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-termexperience. J Surg Oncol, 2008. 97: 487.
89. Ozsahin, M., et al. Treatment of penile carcinoma: to cut or not to cut? Int J Radiat Oncol Biol Phys, 2006. 66: 674.
90. Pagliaro, L.C., et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol, 2010. 28: 3851.
91. Paoli, J., et al. Penile intraepithelial neoplasia: results of photodynamic therapy. Acta Derm Venereol, 2006. 86: 418.
92. Parkin, D.M., et al. Chapter 2: Th e burden of HPV-related cancers. Vaccine, 2006. 24 Suppl 3: S3/11.
93. Pedrick T.J., Wheeler W., Riemenschneider H. Combined modality therapy for locally advanced penile squamous cell carcinoma. American Journal of Clinical Oncology. 1993;16(6):501-5.
94. Philippou, P., et al. Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control. J Urol, 2012. 188: 803.
95. Piva, L., et al. [Th erapeutic alternatives in the treatment of class T1N0 squamous cell carcinoma of the penis: indications and limitations]. Arch Ital Urol Androl, 1996. 68: 157.
96. Pizzocaro, G., et al. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol, 1988. 27: 823.
97. Pizzocaro, G., et al. Taxanes in combination with cisplatin and fl uorouracil for advanced penile cancer: preliminary results. Eur Urol, 2009.55: 546.
98. Rees, R.W., et al. pT2 penile squamous cell carcinomas: cavernosus vs. spongiosus invasion. Eur Urol Suppl, 2008. 7: 111.
99. Robinson R., Marconi L., MacPepple E. et al. Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. European Urology. 2018;74(1):76-83.
100. Rosevear, H.M., et al. Utility of (1)(8)F-FDG PET/CT in identifying penile squamous cell carcinoma metastatic lymph nodes. Urol Oncol, 2012. 30: 723.
101. Rothenberger, K.H., et al. [Laser therapy of penile carcinoma]. Urologe A, 1994. 33: 291.
102. Saisorn, I., et al. Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int, 2006. 97: 1225.
103. Schlenker, B., et al. Organ-preserving neodymium-yttrium-aluminium-garnet laser therapy for penile carcinoma: a long-term follow-up. BJU Int, 2010. 106: 786.
104. Shabbir, M., et al. Glans resurfacing for the treatment of carcinoma in situ of the penis: surgical technique and outcomes. Eur Urol, 2011.59: 142.
105. Sharma, P., et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer aft er lymph node dissection: a multi-institutional study. Urol Oncol, 2015. 33: 496 e17.
106. Shindel, A.W., et al. Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol, 2007. 178: 1980.
107. Stankiewicz, E., et al. HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Mod Pathol, 2009. 22: 1160
108. Stern, R.S. Th e risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol, 2012. 66: 553.
109. Stuiver, M.M., et al. Early wound complications aft er inguinal lymphadenectomy in penile cancer: a historical cohort study and risk-factor analysis. Eur Urol, 2013. 64: 486.
110. Tauber, R., et al. Inguinal lymph node dissection: epidermal vacuum therapy for prevention of wound complications. J Plast Reconstr Aesthet Surg, 2013. 66: 390.
111. Tietjen, D.N., et al. Laser therapy of squamous cell dysplasia and carcinoma of the penis. Urology, 1998. 52: 559.
112. Tobias-Machado, M., et al. Video endoscopic inguinal lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma. J Urol, 2007. 177: 953.
113. Van Bezooijen, B.P., et al. Laser therapy for carcinoma in situ of the penis. J Urol, 2001. 166: 1670.
114. Van Howe, R.S., et al. Th e carcinogenicity of smegma: debunking a myth. J Eur Acad Dermatol Venereol, 2006. 20: 1046.
115. Veeratterapillay, R., et al. Oncologic Outcomes of Penile Cancer Treatment at a UK Supraregional Center. Urology, 2015. 85: 1097.
116. Weldrick, C., et al. A comparison of fi brin sealant versus standard closure in the reduction of postoperative morbidity aft er groin dissection: A systematic review and meta-analysis. Eur J Surg Oncol, 2014. 40: 1391.
117. Windahl, T., et al. Combined laser treatment for penile carcinoma: results aft er long-term followup. J Urol, 2003. 169: 2118.
118. Winters B.R., Kearns J.T., Holt S.K. et al. Is there a benefit to adjuvant radiation in stage III penile cancer after lymph node dissection? Findings from the National Cancer Database. Urology Oncology. 2018;36(3):92.e11-92.e16.
119. Winters, B.R., et al. Predictors of Nodal Upstaging in Clinical Node Negative Patients With Penile Carcinoma: A National Cancer Database Analysis. Urology, 2016. 96: 29.
120. Wu J., Cheng K., Yuan L. et al. Recurrent Penile Squamous Cell Carcinoma Successfully Treated With Cetuximab, Chemotherapy, and Radiotherapy. Clinical Genitourinary Cancer. 2016 Feb;14(1):e135-7.
121. Yao, K., et al. Modifi ed technique of radical inguinal lymphadenectomy for penile carcinoma: morbidity and outcome. J Urol, 2010. 184: 546.
122. Zargar-Shoshtari K., Djajadiningrat R., Sharma P. et al. Establishing Criteria for Bilateral Pelvic Lymph Node Dissection in the Management of Penile Cancer: Lessons Learned from an International Multicenter Collaboration. Journal of Urology. 2015;194(3):696-701.
123. Zhu, Y., et al. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urol Int, 2010. 85: 334.
124. Zou, Z.J., et al. Radiocolloid-based dynamic sentinel lymph node biopsy in penile cancer with clinically negative inguinal lymph node: an updated systematic review and meta-analysis. Int Urol Nephrol, 2016. 48: 2001.
125. Zreik A, Rewhorn M, Vint R, Khan R, Hendry D. Carbon dioxide laser treatment of penile intraepithelial neoplasia. Surgeon. 2017 Dec;15(6):321-324. doi: 10.1016/j.surge.2016.11.001.
Опубликована
2022-12-12
Как цитировать
АНИЩЕНКО, А. А. et al. Современное состояние проблемы комбинированного лечения местно-распрастраненного плоскоклеточного рака полового члена. Новообразование, [S.l.], v. 14, n. 4, p. 154-164, дек. 2022. ISSN 2521-117X. Доступно на: <http://donetsk-onco.com/neoplasm/index.php/Neoplasm/article/view/408>. Дата доступа: 02 мар. 2024
Раздел
Обзоры литературы

Наиболее читаемые статьи этого автора (авторов)

Особенность: этот модуль требует, что бы был включен хотя бы один модуль статистики/отчетов. Если ваши модули статистики возвращают больше одной метрики, то пожалуйста также выберите главную метрику на странице настроек сайта администратором и/или на страницах настройки управляющего журналом.